Exploring Recent Developments in the Treatment of Patients with HR+ Metastatic Breast Cancer - Episode 4

Exploring Recent Developments in the Treatment of Patients With Hormone Receptor– Positive Breast Cancer

A select group oncology experts met to engage in a virtual discussion workshop moderated by oncologist Erika Hamilton, MD. The overall objectives were to review recent data on therapeutic advances in HR+ BC. This article summarizes data from recent trials in early HR+ and TNBC; HR+ metastatic BC, focusing on use of CDK4/6 inhibitors in the first line and second line and beyond; and promising new endocrine therapies that may represent the future direction of HR+ cancer treatment.

EP. 1: Dr. Graff on Initial Steps for Treating Metastatic HR-Positive Breast Cancer
EP. 2: Dr. O’Regan on the Development of Oral SERDs in Breast Cancer
EP. 3: Dr. Litton on Remaining Questions in ESR1-Mutated Breast Cancer
Now Viewing
EP. 4: Exploring Recent Developments in the Treatment of Patients With Hormone Receptor– Positive Breast Cancer

Related Content:

Exploring Recent Developments in the Treatment of Patients with HR+ Metastatic Breast Cancer
Dr. Litton on Remaining Questions in ESR1-Mutated Breast Cancer
Dr. O’Regan on the Development of Oral SERDs in Breast Cancer
Dr. Graff on Initial Steps for Treating Metastatic HR-Positive Breast Cancer